Literature DB >> 10510333

Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation.

Y Tsutsumi1, H Matsubara, H Masaki, H Kurihara, S Murasawa, S Takai, M Miyazaki, Y Nozawa, R Ozono, K Nakagawa, T Miwa, N Kawada, Y Mori, Y Shibasaki, Y Tanaka, S Fujiyama, Y Koyama, A Fujiyama, H Takahashi, T Iwasaka.   

Abstract

Angiotensin II (Ang II) is a potent vasopressor peptide that interacts with 2 major receptor isoforms - AT1 and AT2. Although blood pressure is increased in AT2 knockout mice, the underlying mechanisms remain undefined because of the low levels of expression of AT2 in the vasculature. Here we overexpressed AT2 in vascular smooth muscle (VSM) cells in transgenic (TG) mice. Aortic AT1 was not affected by overexpression of AT2. Chronic infusion of Ang II into AT2-TG mice completely abolished the AT1-mediated pressor effect, which was blocked by inhibitors of bradykinin type 2 receptor (icatibant) and nitric oxide (NO) synthase (L-NAME). Aortic explants from TG mice showed greatly increased cGMP production and diminished Ang II-induced vascular constriction. Removal of endothelium or treatment with icatibant and L-NAME abolished these AT2-mediated effects. AT2 blocked the amiloride-sensitive Na(+)/H(+) exchanger, promoting intracellular acidosis in VSM cells and activating kininogenases. The resulting enhancement of aortic kinin formation in TG mice was not affected by removal of endothelium. Our results suggest that AT2 in aortic VSM cells stimulates the production of bradykinin, which stimulates the NO/cGMP system in a paracrine manner to promote vasodilation. Selective stimulation of AT2 in the presence of AT1 antagonists is predicted to have a beneficial clinical effect in controlling blood pressure.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10510333      PMCID: PMC408562          DOI: 10.1172/JCI7886

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  52 in total

1.  Role of intron 1 in smooth muscle alpha-actin transcriptional regulation in activated mesangial cells in vivo.

Authors:  N Kawada; T Moriyama; A Ando; T Koyama; M Hori; T Miwa; E Imai
Journal:  Kidney Int       Date:  1999-06       Impact factor: 10.612

2.  Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin.

Authors:  D A Scheuer; M H Perrone
Journal:  Am J Physiol       Date:  1993-05

3.  Kallikrein release by vascular tissue.

Authors:  H Nolly; O A Carretero; A G Scicli
Journal:  Am J Physiol       Date:  1993-10

4.  Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia.

Authors:  T Sugaya; S Nishimatsu; K Tanimoto; E Takimoto; T Yamagishi; K Imamura; S Goto; K Imaizumi; Y Hisada; A Otsuka
Journal:  J Biol Chem       Date:  1995-08-11       Impact factor: 5.157

5.  Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors.

Authors:  M Mukoyama; M Nakajima; M Horiuchi; H Sasamura; R E Pratt; V J Dzau
Journal:  J Biol Chem       Date:  1993-11-25       Impact factor: 5.157

6.  Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation.

Authors:  N Seyedi; X Xu; A Nasjletti; T H Hintze
Journal:  Hypertension       Date:  1995-07       Impact factor: 10.190

7.  Angiotensin II binding activity in cultured porcine arterial endothelial cells.

Authors:  C Mineo; H Shimizu; K Takada; T Imanaka; T Takano
Journal:  Biochem Pharmacol       Date:  1994-11-16       Impact factor: 5.858

8.  pH dependence of the action of arginine vasopressin in renal collecting tubule.

Authors:  S Ishikawa; K Okada; T Saito
Journal:  Am J Physiol       Date:  1992-05

9.  Subtype 2 of angiotensin II receptors controls pressure-natriuresis in rats.

Authors:  M Lo; K L Liu; P Lantelme; J Sassard
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

10.  The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells.

Authors:  M Stoll; U M Steckelings; M Paul; S P Bottari; R Metzger; T Unger
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

View more
  101 in total

1.  The interaction of nitric oxide, bradykinin, and the angiotensin II type 2 receptor: lessons learned from transgenic mice.

Authors:  C D Searles; D G Harrison
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

Review 2.  Treatment of coexisting diabetes and hypertension.

Authors:  N M Kaplan
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

3.  Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism.

Authors:  R Weidenbach; R Schulz; P Gres; M Behrends; H Post; G Heusch
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 4.  Progress in focus: recent advances in histochemistry and cell biology.

Authors:  Esther Asan
Journal:  Histochem Cell Biol       Date:  2002-11-27       Impact factor: 4.304

5.  Endothelial AT(2)-receptors: chicken or egg?

Authors:  Paul M Vanhoutte
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

Review 6.  Angiotensin AT2 receptors: cardiovascular hope or hype?

Authors:  Robert E Widdop; Emma S Jones; Ruth E Hannan; Tracey A Gaspari
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

7.  Bradykinin antagonist counteracts the acute effect of both angiotensin-converting enzyme inhibition and of angiotensin receptor blockade on the lower limit of autoregulation of cerebral blood flow.

Authors:  Sigurdur T Sigurdsson; Olaf B Paulson; Arne Høj Nielsen; Svend Strandgaard
Journal:  J Cereb Blood Flow Metab       Date:  2013-12-11       Impact factor: 6.200

Review 8.  Angiotensin II type-2 receptor-specific effects on the cardiovascular system.

Authors:  Ying Li; Xiao-Hui Li; Hong Yuan
Journal:  Cardiovasc Diagn Ther       Date:  2012-03

9.  Angiotensin II subtype AT1 receptor blockade prevents hypertension and renal insufficiency induced by chronic NO-synthase inhibition in rats.

Authors:  M Hropot; K H Langer; Gabriele Wiemer; H Grötsch; W Linz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-25       Impact factor: 3.000

Review 10.  The choice of antihypertensive drugs in patients with diabetes: angiotensin II and beyond.

Authors:  Kambiz Kalantarinia; Helmy M Siragy
Journal:  Curr Diab Rep       Date:  2002-10       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.